EP3538106A4 - PROTECTIVE EFFECT OF DMPC, DMPG, DMPC / DMPG, LYSOPG AND LYSOPC AGAINST MEDICINAL PRODUCTS THAT CAUSE CANALOPATHIA - Google Patents

PROTECTIVE EFFECT OF DMPC, DMPG, DMPC / DMPG, LYSOPG AND LYSOPC AGAINST MEDICINAL PRODUCTS THAT CAUSE CANALOPATHIA Download PDF

Info

Publication number
EP3538106A4
EP3538106A4 EP17869854.4A EP17869854A EP3538106A4 EP 3538106 A4 EP3538106 A4 EP 3538106A4 EP 17869854 A EP17869854 A EP 17869854A EP 3538106 A4 EP3538106 A4 EP 3538106A4
Authority
EP
European Patent Office
Prior art keywords
dmpg
dmpc
lysopg
protective effect
against drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17869854.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3538106A1 (en
Inventor
Lawrence Helson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/347,381 external-priority patent/US10117881B2/en
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of EP3538106A1 publication Critical patent/EP3538106A1/en
Publication of EP3538106A4 publication Critical patent/EP3538106A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17869854.4A 2016-11-09 2017-11-09 PROTECTIVE EFFECT OF DMPC, DMPG, DMPC / DMPG, LYSOPG AND LYSOPC AGAINST MEDICINAL PRODUCTS THAT CAUSE CANALOPATHIA Pending EP3538106A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/347,381 US10117881B2 (en) 2011-06-03 2016-11-09 Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
PCT/US2017/060936 WO2018089687A1 (en) 2016-11-09 2017-11-09 Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies

Publications (2)

Publication Number Publication Date
EP3538106A1 EP3538106A1 (en) 2019-09-18
EP3538106A4 true EP3538106A4 (en) 2021-03-24

Family

ID=62109333

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17869854.4A Pending EP3538106A4 (en) 2016-11-09 2017-11-09 PROTECTIVE EFFECT OF DMPC, DMPG, DMPC / DMPG, LYSOPG AND LYSOPC AGAINST MEDICINAL PRODUCTS THAT CAUSE CANALOPATHIA

Country Status (8)

Country Link
EP (1) EP3538106A4 (zh)
JP (1) JP2019533692A (zh)
KR (3) KR20230110823A (zh)
CN (1) CN110167562A (zh)
AU (1) AU2017357916B2 (zh)
CA (1) CA3042459C (zh)
MX (1) MX2019005141A (zh)
WO (1) WO2018089687A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
MX2019013714A (es) 2017-05-16 2020-07-14 Bow River LLC Metodos de tratamiento.
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
JP2024039728A (ja) * 2022-09-12 2024-03-25 賢一郎 蓮見 抗腫瘍免疫応答増強剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167212A2 (en) * 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
WO2015095576A1 (en) * 2013-12-18 2015-06-25 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812312A (en) * 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
JPH10279487A (ja) * 1997-04-01 1998-10-20 Nippon Shokuhin Kako Co Ltd 脂質代謝改善剤
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
US9447027B2 (en) * 2010-10-22 2016-09-20 The General Hospital Corporation Treating long QT syndrome
US10117881B2 (en) * 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
AU2015269699B2 (en) * 2014-06-03 2020-08-13 Avanti Polar Lipids, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167212A2 (en) * 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
WO2015095576A1 (en) * 2013-12-18 2015-06-25 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel

Also Published As

Publication number Publication date
MX2019005141A (es) 2019-09-26
CA3042459C (en) 2022-08-16
AU2017357916B2 (en) 2020-11-26
EP3538106A1 (en) 2019-09-18
WO2018089687A1 (en) 2018-05-17
JP2019533692A (ja) 2019-11-21
AU2017357916A1 (en) 2019-05-30
CA3042459A1 (en) 2018-05-17
KR20190067918A (ko) 2019-06-17
CN110167562A (zh) 2019-08-23
KR20200108371A (ko) 2020-09-17
KR20230110823A (ko) 2023-07-25

Similar Documents

Publication Publication Date Title
EP3151837A4 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
EP3538106A4 (en) PROTECTIVE EFFECT OF DMPC, DMPG, DMPC / DMPG, LYSOPG AND LYSOPC AGAINST MEDICINAL PRODUCTS THAT CAUSE CANALOPATHIA
EP3442706A4 (en) SAMPLE COLLECTION AND PRESERVATION DEVICES, SYSTEMS AND METHODS
EP3210364B8 (en) Systems and methods for application security analysis
EP3463248A4 (en) DEVICES AND METHOD FOR USING MEDICAL DEVICES
EP3320347A4 (en) SYSTEMS, METHODS AND DEVICES FOR SELF-DIGITIZING SAMPLES
EP3197518A4 (en) Medicament preparation and treatment devices, methods, and systems
EP3551835A4 (en) WELL HEAD SYSTEMS AND METHODS
EP3265217A4 (en) Tumbler systems and methods
EP3420456B8 (en) Anti-replay systems and methods
EP3125970A4 (en) Medical access port, systems and methods of use thereof
EP3405634A4 (en) DOOR HOLDING DEVICE AND SECURITY SYSTEM
EP3400050A4 (en) DEVICE FOR RELEASE OF MEDICINE AND USE
EP3150634A4 (en) Anti-muc1 antibody or antigen-binding fragment of same, and use thereof
EP3510986A4 (en) MOBILITY DEVICE AND MOBILITY SYSTEM
EP3110352A4 (en) Spinal cage device, system, and methods of assembly and use
EP3209766A4 (en) Tissue sample processing system and associated methods
EP3100683A4 (en) Photoacoustic signal-processing device, photoacoustic signal-processing system, and photoacoustic signal-processing method
EP3435665A4 (en) MONITORING AND MONITORING SYSTEM
EP3488431A4 (en) SECURITY CONTROL SYSTEM AND METHODS
EP3537306A4 (en) DEVICE FOR ENTRANCE PREVENTION, METHOD FOR PREVENTION AND PROGRAM FOR PREVENTION
EP3509413A4 (en) SYSTEMS AND METHODS FOR OBTAINING MEDICAL CANNABIS
EP3136948A4 (en) Systems and methods for non-intrusive drug impairment detection
EP3483873A4 (en) NOISE REDUCTION DEVICE AND NOISE REDUCTION SYSTEM
EP3419267A4 (en) EMERGENCY NOTIFICATION DEVICE AND EMERGENCY NOTIFICATION SYSTEM

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/08 20060101ALI20210218BHEP

Ipc: A61K 31/683 20060101AFI20210218BHEP

Ipc: A61P 9/00 20060101ALI20210218BHEP

Ipc: A61K 9/127 20060101ALI20210218BHEP

Ipc: A61K 31/506 20060101ALI20210218BHEP

Ipc: A61K 45/06 20060101ALI20210218BHEP

Ipc: A61P 43/00 20060101ALI20210218BHEP

Ipc: A61P 9/06 20060101ALI20210218BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240314